Comfort Level Rising With Voluntary Genomic Data Submission
Executive Summary
Three years into FDA's Voluntary Genomic Data Submission program, companies are more comfortable with the agency's ability to separate the review of the voluntary data from regulatory actions, according to FDA Associate Director of Genomics Felix Freuh
You may also be interested in...
FDA Nears Target Goal For Voluntary Genomic Data Submissions
FDA expects to reach its annual target of 20 submissions for the first time since the Voluntary Genomic Data Submission program began in 2005
FDA Nears Target Goal For Voluntary Genomic Data Submissions
FDA expects to reach its annual target of 20 submissions for the first time since the Voluntary Genomic Data Submission program began in 2005
CDER Updates, In Brief
What is a reportable premarket adverse event?: FDA continues to consider how to define the serious and unexpected AEs that must be reported during the premarket period. The standard in the safety reporting rule proposed four years ago calls for "virtually everything" to be submitted, CDER Office of Medical Policy Director Bob Temple concedes at the Drug Information Association annual meeting in Atlanta, June 21 (1"The Pink Sheet" March 17, 2003, p. 9). "Nobody likes that very much and ... we're not so crazy about it either," so it is the subject of close scrutiny...